Weil, Goodwin Steer Sanofi's Up To $1.45B Bet On Drug Co.
Sanofi said Monday it's reached an agreement to buy clinical-stage biopharmaceutical company Kymab and its potential cancer and inflammatory disease treatments in a deal worth up to $1.45 billion guided by...To view the full article, register now.
Already a subscriber? Click here to view full article